Neurogene (NGNE) Net Equity Issued and Repurchased (2025)

Neurogene's (NGNE) quarterly Net Equity Issued and Repurchased came in at $20.6 million in Q4 2025.

Neurogene (NGNE) Net Equity Issued and Repurchased (2025) Analysis & Trends

Neurogene (NGNE) has 1 years of Net Equity Issued and Repurchased data on file, last reported at $20.6 million in Q4 2025.

Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $20.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.6 million (changed N/A YoY) and the FY2025 annual result came in at $30.4 million, changed N/A from the prior year.
Net Equity Issued and Repurchased steadied at $20.6 million in Q4 2025.
In the past five years, Net Equity Issued and Repurchased ranged from a high of $20.6 million in Q4 2025 to a low of $20.6 million in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Equity Issued and Repurchased (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	49.20 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	141.90 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Neurogene	815.03 Mn	815.03 Mn	-	-

Download Data

Date	Value
Dec 31, 2025	20.58 Mn
Dec 31, 2025	20.58 Mn